Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial

Jens Bollerslev, Jostein Hallén, Kristian J Fougner, Anders Palmstrøm Jørgensen, Cybele Kristo, Hans Fagertun, Ola Gudmundsen, Pia Burman and Thomas Schreiner

Section of Endocrinology, The National Hospital, Oslo, Norway. The Norwegian University of Sport and PE, Oslo, Norway. Medical Department, Section of Endocrinology, Trondheim University Hospital, Trondheim, Norway. Department of Endocrinology, Aker University Hospital, Oslo, Norway. Capturo AS, Kjeller, Norway. Scandinavian Clinical Research AS, Kjeller, Norway. Department of Endocrinology, University Hospital Malmo University Hospital, Malmo, Sweden

(Correspondence should be addressed to J Bollerslev, Section of Endocrinology, Department of Medicine, National University Hospital, N-0027 Oslo, Norway; Email: jens.bollerslev@klinmed.uio.no)

Abstract

Fifty-five patients with adult-onset GH deficiency (mean age, 49 years) were enrolled in a placebo-controlled, crossover study to investigate the effects of GH therapy on exercise capacity, body composition, and quality of life (QOL). GH and placebo were administered for 9 months each, separated by a 4-month washout period. GH therapy was individually dosed to obtain an IGF-I concentration within the normal range for age and sex. The final mean daily dose of GH was 1.2 IU/day for men and 1.8 IU/day for women. Mean IGF-I concentration at baseline was higher in men than in women (95±33 vs 68±41 μg/l respectively; P, 0.04) and increased to a similar level on GH therapy. Body fat mass was reduced by 1.9±2.9 kg and lean body mass was increased by 1.8±2.8 kg (P = 0.0001 for each) with GH treatment. Total and low-density cholesterol levels decreased. Absolute maximal oxygen uptake increased by 6% (P = 0.01), relative to body weight by 9% (P = 0.004), and there was a trend toward increased endurance performance by 7% (P = 0.07). There were no significant effects on QOL. In conclusion, treatment with a low, physiologic dose of GH produced positive effects on body composition and lipids and improved exercise capacity, likely to be of clinical relevance. No changes in QOL were seen, possibly because of a good QOL at baseline.

European Journal of Endocrinology 153 379–387

Introduction

The syndrome of growth hormone deficiency (GHD) is well established, and it encompasses unfavorable changes in body composition and lipid profiles, reduced muscle strength and exercise capacity, and impaired quality of life (QOL) (1, 2). Patients with long-standing GHD are less healthy than the normal population (3), and long-term follow-up studies of patients with hypopituitarism have shown reduced life expectancy because of cardiovascular and cerebrovascular disease (4–6). GHD seems to contribute to increased vascular morbidity and mortality rates (7, 8); thus, growth hormone (GH) replacement therapy is likely to benefit patients with GHD because it normalizes body composition, improves lipid profiles, and may reduce cardiovascular risk factors (9–13); however, no outcomes studies are available.

GH replacement therapy in adult-onset GHD (AOGHD) increases lean body mass (LBM) (10) and muscle mass (9, 14), even at low doses. However, its effect on muscle strength has been controversial. In smaller, relatively short-term studies, GH therapy had no significant effect on muscle strength despite an increase in muscle mass (14, 15). In long-term (≥2 years), open-label studies, age- and sex-specific increases, and normalization of muscle mass and strength were found with treatment (16, 17).

A limited number of placebo-controlled studies have assessed the effect of GH replacement therapy on exercise and endurance capacity (Table 1) (14, 15, 18–27). In three studies in adults with GHD, a significant increase in endurance capacity (i.e. work performed) was reported with high doses of GH (14, 23, 26). In a prospective, open-label study using a lower GH dose (median, 5.0–5.3 μg/kg per day), treatment for 12 months demonstrated a significant improvement in cardiac performance and in exercise endurance capacity (9). To date, no controlled study has investigated the effect of a low, physiologic dose of GH therapy on maximal oxygen uptake (vo2max) and endurance capacity in patients with AOGHD.
Table 1 Placebo-controlled studies of the effect of recombinant GH therapy on physical exercise.

<table>
<thead>
<tr>
<th>Author/citation</th>
<th>Study design/patients</th>
<th>GH dose / duration</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hoffman et al. (18)</td>
<td>MC, Ran, DB, PC 166 patients with AO-GHD</td>
<td>GH 0.0125 mg/kg per day increased to 0.025 mg/kg per day or decreased to 0.00625 mg/kg per day for 12 months</td>
<td>No significant effect on strength or endurance (measured by dynamometry for knee extensors)</td>
</tr>
<tr>
<td>Thomas et al. (19)</td>
<td>DB, PC, CX 10 patients with GHD*</td>
<td>GH 6 μg/kg LBM for 3 months</td>
<td>No additional effect of GH vs exercise as measured by peak oxygen uptake (VO₂ peak) and ventilation threshold</td>
</tr>
<tr>
<td>Rodriguez-Arnao et al. (15)</td>
<td>Ran, DB, PC 35 patients with GHD (28 with AO-GHD)</td>
<td>GH 0.125 IU/kg per week for 4 weeks followed by 0.25IU/kg per week for 6 months (open label)</td>
<td>No increase on aerobic capacity (measured by an incremental walking test on a treadmill)</td>
</tr>
<tr>
<td>Vahl et al. (20)</td>
<td>Ran DB, PC 27 patients with AO-GHD</td>
<td>GH 21U/m² per day for 12 months</td>
<td>Improved exercise capacity (VO₂ max measured by bicycle ergometry) was recorded</td>
</tr>
<tr>
<td>Gullestad et al. (21)</td>
<td>DB, PC 20 patients with CO-GHD</td>
<td>GH 12 μg/kg per day for 6 months then 36 months (open-label)</td>
<td>Exercise capacity increased significantly with GH as assessed by time to exhaustion (+0.8 min), total accumulated work (+11.6 kJ), and peak VO₂ (P &lt; 0.05 vs PC for each)</td>
</tr>
<tr>
<td>Jorgensen et al. (14)</td>
<td>Ran, DB Parallel 29 patients with AO-GHD</td>
<td>GH 21U/m² per day for 12 months</td>
<td>Significant treatment effect in exercise capacity, 11.6±5.6 (±GH vs PC; P &lt; 0.05 as measured by ergometer exercise)</td>
</tr>
<tr>
<td>Johannsson et al. (22)</td>
<td>Ran, DB, PC, CX 7 patients with GHD* 21 healthy subjects</td>
<td>GH 0.5 IU/week for 6 months then 42 months (open label)</td>
<td>A beneficial effect on exercise capacity was observed (measured by computerized bicycle exercise electrocardiography)</td>
</tr>
<tr>
<td>Nass et al. (23)</td>
<td>DB, PC 20 patients with AO-GHD</td>
<td>GH 12.5 μg/kg body weight per day for 6 months (open-label)</td>
<td>Improvement in exercise capacity (+35 W, P &lt; 0.5 vs PC) measured by bicycle spiroergometer and VO₂ max (+68 ml/min per kg body weight; P &lt; 0.01 vs PC)</td>
</tr>
<tr>
<td>Beshyah et al. (24)</td>
<td>Ran, DB PC 40 GHD hypopituitary patients*</td>
<td>GH 0.04 IU/kg per day 6 months then 1 months (open-label)</td>
<td>Exercise time increased significantly at 6, 12 and 18 months</td>
</tr>
<tr>
<td>Whitehead et al. (25)</td>
<td>DB, PC, CX 14 adults with AO-GHD</td>
<td>GH 0.07 IU/kg body weight daily for 6 months</td>
<td>Exercise capacity increased significantly (+25 vs -8.5 W; P &lt; 0.05 vs PC) as did max O₂ consumption (+0.24 vs +0.06 l/min; P &lt; 0.05 vs PC)</td>
</tr>
<tr>
<td>Cuneo et al. (26)</td>
<td>DB, PC 24 adults with GHD</td>
<td>GH 0.071 IU/kg body weight daily for 6 months</td>
<td>Improved/normalized maximal exercise performance (+24.6 vs +9.7 W; P = 0.047 vs PC) (measured by incremental ergometry) and VO₂ max (+406 vs +133 ml/min; P = 0.016 vs PC) and improved submaximal exercise performance</td>
</tr>
<tr>
<td>Jorgensen et al. (27)</td>
<td>Ran, DB, PC, CX 11 adults with MPD 11 adults with IGHD</td>
<td>GH 21U/m² per day for 4 months</td>
<td>Exercise capacity (measured by bicycle exercise) was significantly increase (60.8 vs 54.2 kJ; P &lt; 0.05 vs PC)</td>
</tr>
</tbody>
</table>

CO-GHD = childhood-onset GH deficiency, CX = crossover, DB = double blind, IGHD = isolated GH deficiency, MPD = multiple pituitary deficiencies; PC = placebo-controlled or placebo, MC = multicenter, Ran = randomized, W = watt.

* Not specified whether adult or childhood onset.
Impaired QOL is of interest as an indication for GH therapy and the effect of GH treatment may be more pronounced in patients with profound symptoms. Previous studies on the effects of GH replacement therapy on QOL in patients with AO-GHD have provided inconsistent results (28). This may be related to a number of factors, including the type of QOL questionnaire used, pretreatment conditions, duration of disease, social environment, and the dose of GH (28). Moreover, in most previous studies, higher doses of GH were used than are used today, and these studies did not take sex, age, or patient sensitivity to GH into consideration.

The aim of the present study was to investigate the effects and potential benefits of physiologic GH replacement therapy on exercise endurance capacity, muscle strength, \( \text{vo}_{2\max} \), body composition, lipid profile, and QOL in GH-naive patients with AO-GHD.

Subjects and methods

Subjects

Fifty-five subjects (31 men and 24 women; mean age, 49 years (range, 26–62 years)) who had had severe AO-GHD for at least 2 years (mean duration, 4.0 (range, 0.3–12.4 years)) and who had never been treated with GH were randomly assigned to treatment with GH replacement therapy or placebo. Severe GHD was defined as a peak GH response to a stimulation test (insulin tolerance test with a nadir glucose level \( \leq 2.2\, \text{mmol/l} \)) less than 3 \( \mu \text{g/l} \). All subjects with multiple pituitary insufficiencies received stable doses of substitution therapy with other hormones for at least 6 months before study entry. Computed tomography or magnetic resonance imaging of the pituitary had been performed within 1 year before the inclusion of each subject in the study.

Primary diagnosis for most subjects (37/55; 67%) was pituitary adenoma; most subjects were treated with surgery alone (27/37; 73%) or with a combination of surgery and irradiation (7/37; 19%). One patient (1/37; 3%) was treated with irradiation only, and the other two patients (2/37; 5.4%) were treated with other therapies. Primary diagnosis was craniopharyngioma (7/55; 13%) or parasellar tumor or meningioma (3/55; 5%) for the other additional subjects; two subjects had cystic tumor of unknown origin. Four subjects acquired hypopituitarism in adulthood from Sheehan syndrome and two subjects had idiopathic hypopituitarism. Of the total study population, most subjects (53/55; 96%) had multiple pituitary deficiencies and only two had isolated GHD. Of the 24 women in the study, 15 underwent estrogen replacement therapy. Six women were considered postmenopausal and did not undergo estrogen replacement therapy; the remaining women were evaluated as eugonadal and no patient received dehydroepiandrosterone. Of the 31 men, 22 received testosterone substitution and the remaining were considered to be eugonadal.

Study design

Three centers in Norway participated in this prospective, double-blind, randomized, crossover study. An independent ethics committee approved the study protocol, and written informed consent was obtained from all subjects. Subjects underwent treatment with either recombinant human GH therapy (Genotropin; Pfizer Inc, New York, NY, USA) or placebo in a crossover fashion. Each treatment period lasted 9 months, with a 4-month washout interval between periods.

GH replacement therapy was dosed individually to maintain serum insulin-like growth factor-I (IGF-I) concentrations between the mean \( \pm 1\, \text{S.D.} \) of the sex- and age-related reference range. GH therapy was initiated at a dose of 0.4 IU/day for men and at 0.8 IU/day for women. Dose adjustments were made in increments of 0.4 IU/day every 4 weeks (maximum dose, 2.0 IU/day (men) and 2.8 IU/day (women)) based on IGF-I concentrations and the absence of adverse effects. A physician who was not blinded to the study and who was not participating in subject care guided all dose adjustments, including dose adjustment for subjects receiving placebo. Patients given placebo received the same adjustments as a given parallel patient receiving active treatment.

At the beginning and end of each treatment period, the following parameters were assessed: exercise capacity, muscle strength, body weight, body composition, physical examination findings, and QOL. Fasting blood samples were obtained and analyzed for IGF-I concentration, glucose, glucosylated hemoglobin (HbA1c) insulin concentrations, and lipid profiles. Adverse effects and vital signs were recorded at each of the monthly visits in each treatment period, including baseline visits (ten visits per treatment period). \( \text{vo}_{2\max} \), muscle strength, and QOL tests were performed before baseline (pretest) to familiarize subjects with these procedures.

Physical exercise capacity, muscle strength, and body composition

Exercise tests and muscle strength were conducted in the subjects from the centers in Oslo, \( n = 28 \) for \( \text{vo}_{2\max} \) and \( n = 35 \) for muscle strength) at a single location by one of the investigators (J H). \( \text{vo}_{2\max} \) and time to exhaustion were determined by treadmill walking or running using a stepwise incremental protocol. The exercise test was started at a relatively low intensity to provide a warm-up period; the speed or incline was then increased at 2-min intervals until subjects reached volitional exhaustion. The initial workload was chosen individually according to the pretest, so that the continuous exercising phase lasted from 8 to 12 min. The work intensity increment was fixed for every subject and was chosen so it equaled approximately 1 metabolic equivalent (3.5 ml/(kg x min)).
Heart rate (Siemens SC6000; Siemens Nederland N.V., Hague, The Netherlands), ratings of perceived exertion (29), and ergospirometric values (Oxicon; Erich Jaeger GmbH, Hoechberg, Germany) were registered at the last minute before exhaustion. Blood from the fingertip was taken 1 and 3 min after exhaustion and analyzed for lactate concentrations (YSI 1500 Sport; Yellow Spring Instruments, OH, USA), and the maximal value was registered. Knee extension strength was tested in voluntary isokinetic knee extensions at 60°/s using a Cybex 6000 dynamometer (Lumex, Ronkonkoma, NY, USA). The range of motion was set to a knee angle of 90°–20° from full extension. Subjects performed four warm-up contractions followed by three maximal contractions (30). Dominant leg peak torque was used to measure knee extensor muscle strength. Total body composition was measured by dual-energy X-ray absorptiometry as body fat mass (BFM) and LBM. The two centers in Oslo used Lunar DPX-L, software version 1.31 (Lunar Corp., Madison, WI, USA). The center in Trondheim used the Hologic QDR-4500 (Waltham, MA, USA) in dual-beam mode. Total body imaging was performed and analyzed by one person at each center, as previously described (31).

**QOL assessments**

The primary questionnaire was the sum score of the Hopkins Symptom Checklist-58 (HSCL-58) (32). The range of scores possible on the HSCL-58 questionnaire was 58–232, with low scores indicating better QOL. The generic questionnaire (short form-36 general health survey; SF-36) (33) where higher scores indicate better QOL was also performed. Results of the baseline SF-36 questionnaire used was the assessment of growth hormone deficiency in adults (AGHDA) (35).

**IGF-I and other chemistry profiles**

Biochemical analyses were performed by accredited laboratories according to standard laboratory methods. IGF-I analysis was performed using the commercial kit Immulite (Diagnostic Products Corporation, Los Angeles, CA, USA). The intra-assay coefficient of variation (C.V.) was 4–8% and the interassay C.V. was less than 9%. Insulin, lipids, and other chemistry measurements were performed by routine methods at Furst Laboratory, Oslo, Norway.

**Statistical analyses**

An analysis of covariance (ANCOVA) model that included treatment drug, center, baseline value, sex, and age was presented. Variables analyzed with ANCOVA included the sum score for exercise variables (i.e. VO₂ max (ml/(kg × min) and l/min) endurance time), LBM, BFM, HSCL-58, dimensions of HSCL-58 and SF-36, and sum scores of AGHDA. The difference (month 9 to month 0) was the dependent variable in the ANCOVA models. The direct effect of GH therapy compared with placebo treatment was estimated by the crossover effect, which was calculated by taking the difference between GH and placebo (month 0 to month 9 changes). Using mean values, a point estimate and a two-sided 95% confidence interval of the crossover differences were calculated. Subjects who withdrew in period 1 were excluded from analysis; those subjects participating for at least 3 months of period 2 were included. All tests performed were two sided, and the significance level was set at 5%.

**Results**

**Demographics and baseline characteristics of subjects**

Patient demographics and baseline characteristics for the 55 subjects enrolled in the study are summarized in Table 2. Of those subjects enrolled, seven withdrew from the study (two during placebo treatment, three

<table>
<thead>
<tr>
<th>Description</th>
<th>Subjects (n = 55)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, n (%)</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>31 (56.4)</td>
</tr>
<tr>
<td>Women</td>
<td>24 (43.6)</td>
</tr>
<tr>
<td>Mean age, years (±S.D.)</td>
<td>49 (10)</td>
</tr>
<tr>
<td>Mean weight, kg (±S.D.)</td>
<td>84 (20)</td>
</tr>
<tr>
<td>Mean height, cm (±S.D.)</td>
<td>172 (11)</td>
</tr>
<tr>
<td>Mean body mass index (±S.D.)</td>
<td>28.0 (5.0)</td>
</tr>
<tr>
<td>Men</td>
<td>29.3 (4.9)</td>
</tr>
<tr>
<td>Women</td>
<td>26.4 (4.6)</td>
</tr>
<tr>
<td>HSCL-58 raw scores, mean (±S.D.)a</td>
<td>86.6 (25.2)</td>
</tr>
<tr>
<td>All 58 questions</td>
<td></td>
</tr>
<tr>
<td>Somatization</td>
<td>1.5 (0.5)</td>
</tr>
<tr>
<td>Fearfulness</td>
<td>1.4 (0.5)</td>
</tr>
<tr>
<td>Tension</td>
<td>1.7 (0.6)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>1.4 (0.5)</td>
</tr>
<tr>
<td>Cognition</td>
<td>1.7 (0.6)</td>
</tr>
<tr>
<td>Depression</td>
<td>1.6 (0.5)</td>
</tr>
<tr>
<td>Interpersonal sensitivity</td>
<td>1.5 (0.5)</td>
</tr>
<tr>
<td>Inferiority</td>
<td>1.3 (0.4)</td>
</tr>
<tr>
<td>SF-36 standardized scores, mean (±S.D.)b</td>
<td>84.7 (14.6)</td>
</tr>
<tr>
<td>Physiologic functioning</td>
<td></td>
</tr>
<tr>
<td>Role physical</td>
<td>70.7 (35.7)</td>
</tr>
<tr>
<td>Bodily pain</td>
<td>75.3 (24.2)</td>
</tr>
<tr>
<td>General health</td>
<td>65.7 (24.8)</td>
</tr>
<tr>
<td>Vitality</td>
<td>46.9 (21.8)</td>
</tr>
<tr>
<td>Social functioning</td>
<td>81.9 (22.3)</td>
</tr>
<tr>
<td>Role emotional</td>
<td>73.8 (34.6)</td>
</tr>
<tr>
<td>Mental health</td>
<td>76.8 (18.4)</td>
</tr>
<tr>
<td>Health transition</td>
<td>3.0 (0.4)</td>
</tr>
<tr>
<td>AGHDA, mean (±S.D.)</td>
<td>8.2 (6.9)</td>
</tr>
</tbody>
</table>

AGHDA, mean (±S.D.)a Low score indicates better QOL; bHigh score indicates better quality of life QOL.
during GH treatment and two withdrew prior to the first study dose. Sufficient data were accumulated in the second treatment period to include one of the two subjects in the analysis of efficacy, resulting in a total of 49 study subjects (29 men and 20 women) who were evaluable for efficacy and safety.

**GH doses and IGF-I levels**

Fig. 1 illustrates IGF-I concentrations at baseline compared with age-adjusted IGF-I reference curves. Mean baseline IGF-I concentrations were significantly higher in men \((95 \pm 33 \text{ vs } 68 \pm 41 \mu g/l)\) respectively; \(P < 0.04\). Mean final dose of GH in women \((1.8 \pm 0.8 \text{ IU/day})\) was approximately 50% greater than the dose used in men \((1.2 \pm 0.6 \text{ IU/day}; P = 0.03)\). Women prescribed estrogen replacement therapy \((n = 15)\) tended to require higher doses of GH than women not prescribed estrogen \((n = 9)\) \((2.0 \pm 0.9 \text{ vs } 1.6 \pm 0.3 \text{ IU/day}; P < 0.05)\). The mean time to reach the final GH dose was 3.2 months. During treatment with GH, IGF-I concentrations increased to a similar level in men and women \((217 \pm 65 \text{ and } 186 \pm 70 \mu g/l)\) respectively; \(P = \text{not significant (NS)}\); Fig. 1). In two women the final dose of GH administered did not increase IGF-I to the desired level.

**Exercise capacity and leg muscle strength**

\(\text{VO}_{2\text{max}}\) increased significantly with GH treatment compared with placebo in absolute value \((l/min, 6%; P = 0.01)\) and relative to body weight \((\text{ml/(kg x min), 9%; } P = 0.004)\) (Fig. 2). The crossover difference for endurance performance increased by 0.6 min in favor of GH treatment, representing a 7% increase \((P = 0.07)\). Heart rate, ventilation rate, respiratory exchange ratio, rating of perceived exertion, and lactate concentration at exhaustion were not significantly different between the treatment periods (data not shown). Knee extensor peak torque was \(178.5 \pm 62.8\)
Newton meters (Nm) before and 176.3±62.0 Nm after GH treatment (P = NS).

**Body composition and lipid profile**

LBM increased with GH replacement therapy compared with placebo (1.8±2.8 kg; P = 0.0001) and BFM decreased significantly (1.9±2.9 kg; P = 0.0001). Total and low-density lipoprotein cholesterol concentrations decreased by 0.50 mmol/l (P = 0.004) and 0.47 mmol/l (P = 0.0002) respectively, whereas triglycerides increased by 0.40 mmol/l (P = 0.01) during GH treatment.

**QOL assessments**

QOL was not impaired in most subjects, as is represented by the mean baseline values as assessed by the HSCL-58, the SF-36, and the AGHDA in Table 2. After 9 months of GH treatment, overall QOL in subjects was not significantly different from the reported QOL in those receiving placebo. There was no sex difference in response to treatment. Assessment in patients with HSCL-58 values above the median sum score of 78 showed that there was a marked improvement in women compared with men with respect to the global score (P = 0.033) and in dimensions assessing somatization (P = 0.026), fearfulness (P = 0.003), and tension (P = 0.016). Figure 3 compares baseline SF-36 results of study patients with those of normative Norwegian data (34). Patients with AO-GHD scored lower than the referenced healthy population only in the sum scores vitality and general health.

**Safety**

During active treatment, serum insulin concentrations increased by 33.7 pmol/l (P < 0.02), fasting glucose concentrations increased by 0.49 mmol/l (P = 0.02), and HbA1c increased by 0.14% (P = 0.05). There were no differences in the effect of treatment between women and men. Numbers of adverse effects, changes in vital signs, and physical examination findings were similar in both treatment periods.

**Discussion**

In the present study, a low physiologic dose of GH was associated with improvements in body composition, low-density lipoprotein cholesterol, and exercise capacity. Glucose levels were moderately increased within the normal range. The effects of GH therapy on lipids and glucose metabolism were in accordance with previous studies in patients with GHD (36), which in general have used higher doses of GH. The effect on body composition in the present study was less prominent compared with the observed changes with higher doses of GH (27, 37, 38), a finding that corroborates the work by De Boer et al. (39), in which effects on adiposity were found to be dose dependent.

Previous studies assessing the effects of GH therapy on exercise capacity in patients with GHD have been open labeled (9, 40–44) or have used higher, weight-based or fixed doses of GH (14, 15, 18, 20–23, 25, 26). In the present study, we attempted to reduce a possible placebo effect by using a similar individualized GH dosing regimen during each treatment period. The dose of GH was lower than used in previous controlled studies and took into account the sex-related difference in GH responsiveness in women by using a higher starting dose and allowing for a higher final dose. Using this method, we found that women treated with GH needed a dose approximately 50% greater than that administered to men to obtain the target

![Figure 3](https://www.eje-online.org)  
*Figure 3* SF-36 general health survey baseline results (±S.E.M.) of study population (■) compared with healthy Norwegian subjects (□) (30). The short form dimensions are shown. PF, physical functioning; RP, role physical; RE, role emotional; BP, bodily pain; SF, social functioning; MH, mental health; VT, vitality; GH, general health.
IGF-I concentration and similar effects on body composition and lipids.

In studies of patients with GHD (41, 44, 45), GH treatment with higher doses has been associated with increases of up to 20% in exercise performance. An increase in $\text{VO}_2\text{max}$ of 7–9% as found in this study is likely to be clinically relevant in middle-aged patients, improving daily exercise capacity (46). Physical training per se, in the absence of GHD, typically increases $\text{VO}_2\text{max}$ by 10–20%, depending on training status and genetic predisposition (46).

The improvement in endurance capacity was paralleled by a similar increase in absolute and relative VO$_2$max. Theoretically, the increase in oxygen uptake could be explained, in part, by alterations in LBM. However, adjusting for the change in LBM did not change the results (data not shown), indicating that additional factors are likely to contribute, for instance, an increase in cardiac output (41, 44). Interestingly, physical capacity, as measured in our cohort at baseline, was not correlated with IGF-I concentrations but with baseline QOL (data not shown). Recently, in a controlled study, the potential benefit of combining an exercise program with GH replacement therapy for 3 months in ten patients with GHD was studied (19). A positive effect of training was noted, but no additive effect of GH therapy was observed. Illustrating that physical fitness may influence the extent of change achieved by GH. In our study, we did not find a relation between the baseline exercise capacity and the response to GH.

Muscle strength was not improved by active treatment in this study in accordance with other investigations using GH in physiologic doses (14, 15), although some positive effect has been reported in two long-term, open-label studies (16, 17). The lack of effect in the present study is not surprising, even if muscle mass was greater (LBM, 1.8 kg) during GH therapy than with placebo because muscle strength is determined by several factors, in addition to muscle size (16). It is likely that GH therapy alone, without an adequate weight-training program, is not sufficient to produce an increase in muscle strength (15).

QOL was assessed by a variety of non-specific and disease-specific questionnaires in this study. In contrast to findings in several previous controlled and open-label studies (3, 47, 48), we were unable to demonstrate significant improvements in QOL. Several explanations are possible. Because GH has been in clinical use for several years, our population might have represented a population of patients with slight or vague symptoms (49). This is suggested by the results of the SF-36 questionnaire. Patients scored lower, but not significantly lower, for each of the separate domains compared with normative data. Only the sum scores vitality and general health were significantly reduced, substantiating the minor reduction in psychologic health in our population at baseline. In addition to patient selection, the benefit of GH therapy on QOL in early studies might have been related to higher GH dosing, either throughout the studies or during the initial phases (49).

In conclusion, physiologic and individualized GH replacement therapy aimed at normalizing IGF-I concentration in relation to age in GH-naive patients with AO-GHD was followed by significant improvements in body composition, as well as low-density lipoprotein cholesterol and exercise capacity. Treatment with GH was not associated with changes in the patients’ perceived QOL, probably because these patients had a good QOL at the onset of the study.

Acknowledgements

At the time that the clinical study was completed, P B was an employee in the Department of Endocrine Care for Pfizer Inc., New York, NY, USA. This study was supported by Pfizer Inc., New York, NY, USA.

References


Received 23 March 2005
Accepted 25 May 2005